SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended July 31, 1995 Commission File Number-I7828
GELMAN SCIENCES INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)

MICHIGAN 38-1614806
- ------------------------------------ -------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)

600 SOUTH WAGNER ROAD
ANN ARBOR, MICHIGAN 48103-9019
- ---------------------------------------- -------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code (313) 665-0651

Securities Registered Pursuant to Section 12(b) of the Act:
Name of each exchange on
Title of each class which registered
- ---------------------------------------- -------------------------
COMMON STOCK, PAR VALUE $.10 PER SHARE AMERICAN STOCK EXCHANGE

Securities Registered Pursuant to Section 12(g) of the Act:
None

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
------- --------

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K. ________

The aggregate market value of the registrant's voting stock (Common Stock, $.10
Par Value) held by nonaffiliates of the registrant as of October 24, 1995 was
$147,116,304.

The number of outstanding shares of the registrant's Common Stock, as of
October 24, 1995 was 7,821,762 shares, $.10 Par Value.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Annual Report to Shareholders for the fiscal year ended July
31, 1995, are incorporated by reference into Parts I and II of this report.

Portions of the proxy statement for the 1995 Annual Meeting of Shareholders are
incorporated by reference into Part III of this report.

Portions of the Form 10-Q for the quarterly period ended January 31, 1995, are
incorporated by reference into Part IV of this report.

Exhibit Index at Page 18. Number of Pages 74.
2

PART I

ITEM 1. BUSINESS.

(A) GENERAL DEVELOPMENT OF BUSINESS

Gelman Sciences Inc. (the "Company") was incorporated in 1959. Unless
the context indicates otherwise, the term "Company" includes Gelman Sciences
Inc. and its subsidiaries.

The Company is a global corporation with its major area of business
being the servicing of the industrial, scientific and medical communities with
its expertise in polymeric membranes. The Company provides the means of
separation and purification of various liquids and gases through the
utilization of these membranes. These separation technologies are applied to
various types of filtration, fluid and analysis, medical and clinical
diagnostic devices.

Product engineering support of this technology is the second area of
business for the Company. This includes the development and manufacture of
membranes, filtration equipment and hardware and disposable filtration devices.

(B) FINANCIAL INFORMATION ABOUT INDUSTRY SEGMENTS

The information set forth under Note I to the financial statements
"Operations by Industry Segment and Geographic Area" on pages 23 and 24 of the
Company's 1995 Annual Report to Shareholders is hereby incorporated herein by
reference.

HEALTH PRODUCTS GROUP

The Health Products Group manufactures a variety of specialized
medical disposable filter devices. These products are used in the medical and
health care markets both domestically and internationally. These products are
sold through sales outlets as either standard catalog items or as original
equipment manufacturer ("OEM") products. These OEM products consist of
intravenous fluid in-line filters, transducer protectors and standard small
volume filtration disposable medical filters. Medical device sales have
accounted for 34%, 31% and 31% of total sales for the years ended July 31,
1995, 1994 and 1993, respectively.

The Health Products Group also provides other products for the health
care industry such as membranes, equipment and reagents for clinical diagnostic
testing by electrophoresis. These products, both in domestic and international
markets, are sold by Company sales personnel and a network of distributors.
Microporous membrane media, used in a variety of medical applications, are
provided by the Health Products Group in bulk roll stock for use in products
of OEMs.

2
3

BACKLOG AND RAW MATERIALS

Backlog for the Health Products Group amounted to $8,215,000 and
$8,536,000 at October 21, 1995 and 1994, respectively. It is anticipated that
the current backlog will be completed prior to July 31, 1996. No unusual
sources of supply are required to meet manufacturing requirements.

COMPETITION

Competition in the Health Products Group comes from a variety of
competitors, the two most important of which are Millipore Corporation and Pall
Corporation. Both competitors are significantly larger than the Company.

FILTRATION PRODUCTS GROUP

The Filtration Products Group supplies various configurations of
microfiltration media and hardware to the industrial and scientific
communities. Small diameter filter media and hardware are utilized in research
and industrial laboratories for clarification of solutions, microbiological
analysis of water, and sterilization of substances such as tissue culture
media. The sales of laboratory filters and hardware have accounted for 40%,
44%, and 45% of total sales for years ended July 31, 1995, 1994, and 1993,
respectively.

In the industrial process filtration area, products utilized are in
both large diameter filters and high surface area cartridges for clarification
and sterilization of gases, liquids and chemicals. Typical industrial
customers are in the pharmaceutical, electronics, and beverage industries.
These products are sold both domestically and internationally by Company sales
personnel and a network of distributors. The cartridge and capsule sales have
accounted for 24%, 22% and 21% of total sales for the years ended July 31,
1995, 1994 and 1993, respectively.

BACKLOG AND RAW MATERIALS

Backlog for the Filtration Products Group amounted to $5,922,000 and
$5,892,000 at October 21, 1995 and 1994, respectively. It is anticipated that
the current backlog will be completed prior to July 31, 1996. No unusual
sources of supply are required to meet manufacturing requirements.

COMPETITION

In the Filtration Products Group, the Company's primary competitors
are Millipore Corporation, Pall Corporation and Sartorious Membranfilter GmbH
(in Europe), with whom the Company has entered into a partnership agreement to
supply microfiltration media. The Company's prices for such items are
competitive. In addition, competition in this market area is to a high degree
based on product quality and other technical services.

3
4

GENERAL BUSINESS

EMPLOYEES

Gelman Sciences Inc. employs 720 persons in the United States and 109
persons in non-U.S. operations. The Company relies to a great extent, both
domestically and internationally, on a network of distributors. Domestically
the Company employs 34 sales representatives to work with distributors, make
sales calls in conjunction with their representatives, and handle any technical
support needs that might arise.

PATENTS, TRADEMARKS, LICENSES AND TECHNOLOGICAL CAPABILITY

The Company owns a number of patents and trademarks but does not
consider them to be materially important to its business. The Company relies
to a great extent on its technological skills and product development
achievements to compete effectively.

ENVIRONMENTAL REGULATIONS

Until May 1986, the Company used 1,4-dioxane, an organic chemical, in
manufacturing processes at its main facility in Ann Arbor, Michigan. Over the
years, various storage and waste water disposal methods have been permitted by
the responsible governmental agencies. In January 1986, 1,4-dioxane was
identified in wells near the manufacturing plant. Under a consent judgment
agreed to in October 1992 resolving litigation with the State of Michigan, the
Company is remediating this contamination without admitting wrongdoing.

For a description of the environmental litigation in which the Company is
presently involved, see "Legal Proceedings" Item 3 below, "Management's
Discussion and Analysis of Financial Condition and Results of Operations," at
pages 12 and 13 of the Company's 1995 Annual Report to Shareholders and "Note G
- - Pollution-Related Expenses" to the Company's Consolidated Financial
Statements, at page 22 of the Company's 1995 Annual Report to Shareholders.

4
5

RESEARCH AND DEVELOPMENT

Product development and research activities of the Company are carried
out on location primarily at its Ann Arbor and Pensacola facilities. Such
activities are concentrated primarily on new products and applications. The
Company expended $5,498,000, $4,877,000, and $4,139,000 in fiscal 1995, 1994
and 1993, respectively, for product development and research activities.

(D) FINANCIAL INFORMATION REGARDING GEOGRAPHIC AREAS

EXECUTIVE OFFICERS OF THE REGISTRANT

The following table sets forth the names and ages of the executive
officers of the Company, together with all positions and offices held by such
executive officers. Executive officers are elected annually by, and serve at
the pleasure of, the Board of Directors.

First Elected
Officer of
Name Age Office Held the Company
- ------------------------------ ------ --------------------------------- -------------------

Charles Gelman 63 Chairman of the Board and 1974
Chief Executive Officer

Kim A. Davis 44 President and Chief Operating Officer 1993

James C. Marshall 52 Senior Vice President 1976

Anthony P. Kelly 47 Vice President, Worldwide Sales 1995

Karen A. Radtke 42 Treasurer 1995

Mark A. Sutter 34 Vice President, Research & Development 1992

Edward J. Levitt 51 Secretary and Corporate Counsel 1991

Charles Gelman founded Gelman Sciences Inc. in 1959. He was the
Company's President from 1974 to April 1988 and from October 1990 to May 1993.
He has been the Company's Chairman and Chief Executive Officer since 1974.

Kim A. Davis was elected President and Chief Operating Officer of the
Company, effective May 4, 1993, and elected a Director of the Company,
effective March 18, 1995. Mr. Davis is responsible for worldwide operations
including sales, marketing and manufacturing. From January 1991, Mr. Davis was
chief operating officer of Promega Corporation, a Wisconsin-based biotechnology
company. Prior to joining Gelman Sciences and Promega, Mr. Davis was president
and chief executive officer of a privately-held engineering graphics software
company from November 1989.

5
6

James C. Marshall is the Senior Vice President responsible for
manufacturing operations in Pensacola, Florida. Prior to that, he was
responsible for Ann Arbor Operations, and has worked in the manufacturing
function for the Company for over 30 years.

Anthony P. Kelly was appointed Vice President, Worldwide Sales,
effective September 20, 1995. Mr. Kelly is responsible for selling activities
throughout the world. Mr. Kelly remains Vice President, Sales Asia/Pacific for
Gelman Sciences International, Inc., and a Director and President of Gelman
Sciences Pty. Ltd., the Company's Australian subsidiary.

Karen A. Radtke was appointed Treasurer effective June 5, 1995.
Previously, Ms. Radtke was Treasurer and Tax Director of Hayes Wheels, Inc., a
$500 million international automotive component manufacturer from July 93 to
May 1995. Prior to joining Hayes Wheels, Ms. Radtke served on the General
Motors International Tax Staff since 1988.

Mark A. Sutter was appointed as Vice President, Research &
Development, in May 1992, becoming responsible for all Research & Development
activities. Previously, Mr. Sutter served as Director of Membrane Research &
Development and Cartridge Capsule Product Development and in various marketing
functions for the Company since his hire date of January 1986.

Edward J. Levitt was appointed as Secretary for the Company on March
24, 1994. He was Assistant Vice President-Legal from December 1991 to March
1994. Mr. Levitt was hired in April 1989 as Corporate Counsel and continues to
serve in that capacity.

ITEM 2. PROPERTIES.

The Company owns office and manufacturing facilities located in Ann
Arbor, Michigan containing approximately 180,000 square feet of floor
space. The Company was granted an Industrial Development Bond in July 1989, the
proceeds of which were utilized to purchase land in Pensacola, Florida and
build a 58,000 square foot manufacturing facility which was completed in fiscal
1990. During fiscal 1994, the 1989 Industrial Development Bond was redeemed
The redemption was funded by the issuance of a 1994 Industrial Development
Bond. The amount outstanding under the 1994 Industrial Revenue Bond at July 31,
1995, was $4,697,000. The Company owns 50 acres of vacant land near the Ann
Arbor facility. This is held for resale as part of an out-of-court settlement
related to an environmental lawsuit. The Company also leases buildings in Ann
Arbor and Pleasanton, California containing approximately 58,000 square feet
which are used primarily for office space and manufacturing.

The Company's Australian, British, Canadian, German, Irish, French,
Italian and Japanese subsidiaries lease facilities. The Australian subsidiary
also owns a building containing approximately 43,000 square feet used for
manufacturing. This manufacturing facility is now being leased to a purchaser
of several non-core product lines divested in fiscal 1994. The future
commitments for all non-cancellable facility leases represent $5,732,000.

Substantially all of the existing facilities are used in connection
with the Company's Health and Filtration Product Groups.

6
7

ITEM 3. LEGAL PROCEEDINGS.

The Company, in the normal course of business, is involved in
incidental, routine litigation. In addition, the Company is currently a party
to various legal actions arising under statutes regulating the discharge of
materials into the environment or otherwise protecting the environment. Those
legal actions involving environmental issues are described below. (See
"Environmental Regulations" in Item 1, above.)

Scarbrough, et al. v. Gelman Sciences Inc., et al. (Circuit Court for
Washtenaw County, Michigan, Case No. 88-35594-CE). By Complaint filed August
8, 1988, and amended September 15, 1988, 27 residents of the Westover
subdivision located near the main facility of the Company sued the Company and
8 other defendants for damages associated with alleged contamination of
residential water supplies and for the cost of court-supervised medical
surveillance. The total demand was $3,095,000. On March 9, 1990, plaintiffs
settled with 7 of the 8 other defendants for $100,000. (The suit against the
remaining other defendant was subsequently dismissed by the Court.)
Thereafter, 15 plaintiffs settled with the Company for a total of $175,535.
Twelve plaintiffs refused to settle. On November 30, 1990, a jury returned a
verdict in favor of the 12 plaintiffs, awarding damages totalling $119,756.
After adjustment for the March 9, 1990, settlement between plaintiffs and 7
other defendants, the net jury verdict against the Company was $62,250, plus
interest. On December 11, 1991, the Court awarded the Company costs totalling
$87,529.38, plus interest. The 12 plaintiffs who went to trial appealed the
outcome of the case. On July 27, 1994, the Court of Appeals affirmed the jury
verdict. On September 21, 1994, the Court of Appeals denied plaintiff's Motion
for Rehearing. Plaintiffs filed an Application for Leave to Appeal with the
Michigan Supreme Court. On June 30, 1995, the Supreme Court denied the
Application. Plaintiffs have filed a Motion for Reconsideration, which is
pending.

Campbell, et al. v. Gelman Sciences Inc. (Circuit Court for Washtenaw
County, Michigan, Case No. 91-41524-CE). On July 30, 1991, a complaint was
filed against the Company by 5 individuals in the Westover residential
subdivision located near the main facility of the Company for damages for
anticipated expenses for future medical monitoring asserted to be necessary
because plaintiffs claim they are subject to increased risk of contracting
serious latent diseases as a result of exposure to air and groundwater
contamination allegedly caused by the Company. The plaintiffs are the children
of some individuals who had sued the Company previously in Scarbrough, et al.
v. Gelman Sciences Inc., et al., discussed above. On August 26, 1991, the
Company filed its answer, denying liability and asking the Court to dismiss
this lawsuit. On October 23, 1992, the Court entered an Order granting summary
judgment to the Company. The case was dismissed by Order dated December 11,
1992. The plaintiffs appealed, and, on February 8, 1995, the Michigan Court of
Appeals affirmed the dismissal.

7
8

Dawson, et ano v. Gelman Sciences Inc., et al. (Circuit Court for
Washtenaw County, Michigan, Case No. 92-43975-CE). On November 3, 1992, two
residents in the Evergreen subdivision located near the main facility of the
Company filed a Complaint against the Company, the Chairman of the Company, and
eight other defendants for damages associated with alleged contamination of
residential water supplies. On January 7, 1993, the Company and its Chairman
filed their Answers denying liability and cross-claiming against the
co-defendants. On October 27, 1993, the Court granted the motion of the
Company and its Chairman for summary judgment. An Order dismissing this case
was entered on December 15, 1993. Plaintiffs have filed an appeal of this
dismissal. The appeal is pending.

Laird, et ano v. Gelman Sciences Inc., et ano. (Circuit Court for
Washtenaw County, Michigan, Case No. 93-623 CZ). On May 12, 1993, the two
owners of a business located near the main facility of the Company filed a
Complaint against the Company and its Chairman for damages associated with
alleged contamination of the groundwater supply of that business. On November
8, 1993, the Company and its Chairman filed their Answers denying liability.
On December 1, 1994, the parties agreed to a settlement upon payment by the
Company of $30,000 to the plaintiffs. Payment was made and, on stipulation of
the parties, the case was dismissed on January 3, 1995.

"Thermo Chem" Superfund Site, Muskegon, Michigan. By correspondence
dated January 2, 1992, the United States Environmental Protection Agency
("USEPA") identified the Company as a potentially responsible party ("PRP")
under the Comprehensive Environmental Response, Compensation, and Liability Act
("CERCLA") for past and future response costs in connection with the Thermo Chem
Superfund site, a waste chemical reclamation and disposal site. The USEPA
issued an Administrative Order mandating remediation of the site to a number of
generator PRPs. On July 22, 1994, the Company and the USEPA entered into a
settlement agreement under which the Company agreed to pay $124,100. A USEPA
administrative consent order based on that agreement became effective February
8, 1995, and the Company paid March 10, 1995.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

None

8
9

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON STOCK AND RELATED SHAREHOLDERS MATTERS.

The information required by this item is set forth under the caption
"Stock Prices" on page 10 of the Company's 1995 Annual Report to the
Shareholders, and is hereby incorporated herein by reference.

ITEM 6. SELECTED FINANCIAL DATA.

The information required by this item is set forth under the caption
"Selected Financial Data" on page 11 of the Company's 1995 Annual Report to
Shareholders, and is hereby incorporated herein by reference.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.

The information required by this item is set forth under the caption
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" on pages 12 and 13 of the Company's 1995 Annual Report to
Shareholders, and is hereby incorporated herein by reference. The Company does
not believe that inflation has had a material impact on its results of
operations over the past three years.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

The information required by this item is set forth on pages 14 through
24 of the Company's 1995 Annual Report to Shareholders, and is hereby
incorporated herein by reference.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.

None.

9
10

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

The information required by this item with respect to the Company's
directors is set forth under the caption "Election of Directors" of the
Company's proxy statement for the 1995 Annual Meeting of Shareholders, and is
hereby incorporated herein by reference.

Information called for by this item with respect to the Company's
executive officers is set forth under "Executive Officers of the Registrant" in
Part I of this report.

Based solely on a review of the copies of such forms furnished to the
Company and written representations from the Company's executive officers and
directors, the Company believes that during the last fiscal year all Section
16(a) filing requirements applicable to its executive officers, directors and
greater than ten percent beneficial owners were complied with.

ITEM 11. EXECUTIVE COMPENSATION.

The information required by this item is set forth under the captions
"Election of Directors" and "Compensation of Executive Officers" of the
Company's proxy statement for the 1995 Annual Meeting of Shareholders, and is
hereby incorporated herein by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

The information required by this item is set forth under the captions
"Principal Shareholders" and "Election of Directors" of the Company's proxy
statement for the 1995 Annual Meeting of Shareholders, and is hereby
incorporated herein by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

The information required by this item is set forth under the caption
"Compensation of Executive Officers - Certain Relationships and Related
Transactions" of the Company's proxy statement for the 1995 Annual Meeting of
Shareholders, and is hereby incorporated herein by reference.

10
11

PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.

(a)(1) Financial Statements

The following financial statements and supplementary data are
incorporated by reference from pages 14 through 25 of the Company's
1995 Annual Report to Shareholders:

(A) Consolidated Statements of Operations - Years Ended July 31,
1995, 1994 and 1993.

(B) Consolidated Statements of Stockholders' Equity - Years ended
July 31, 1995, 1994 and 1993.

(D) Consolidated Statements of Cash Flows - Years ended July 31,
1995, 1994 and 1993.

(E) Notes to Consolidated Financial Statements.

(F) Report of Independent Auditors.

(G) Summary of Quarterly Results of Operations - Years ended July
31, 1995 and 1994

(a)(2) Financial Statement Schedules

The following financial statement schedules are submitted in
accordance with Item 14.(d) and are set forth on pages 16 and 17 of
this report:

Report of Independent Auditors

II -- Valuation and Qualifying Accounts - Years ended July 31,
1995, 1994 and 1993.

All other schedules for which provision is made in the applicable accounting
regulations of the Securities and Exchange Commission are not required under
the related instructions or are inapplicable, and therefore have been omitted.

11
12

(a)(3) Exhibits

(3) Articles of Incorporation and Bylaws

(1) Restated Articles of Incorporation, incorporated by
reference from Exhibit (3)(1) to the Company's Form
10-Q for the quarterly period ended January 31, 1995.

(2) Restated Bylaws

(4) Instruments Defining Rights of Security Holders

(1) Pursuant to 17 CFR 229.601(b)(4)(iii), instruments
with respect to long-term debt issues have been
omitted where the amount of securities authorized
under each such instrument does not exceed 10% of the
total consolidated assets of the Company. The
Company hereby agrees to furnish a copy of each such
instrument to the Commission upon its request.

(10) Material Contracts

(1) Deferred Compensation Agreement between the Company
and James C. Marshall, incorporated by reference from
Exhibit 10(3) to the Company's Form 10-K for the year
ended July 31, 1988.

(2) Employment Agreement between the Company and James C.
Marshall, incorporated by reference from Exhibit
10(4) to the Company's Form 10-K for the year ended
July 31, 1989.

(3) 1978 Employee Stock Option Plan, as amended,
incorporated by reference from Exhibit 10(2) to the
Company's Form 10-K for the year ended July 31, 1987.

(4) 1988 Stock Plan, incorporated by reference from
Exhibit 10(6) to the Company's Form 10-K for the year
ended July 31, 1988.

(5) Warrant Agreement, dated December 16, 1987, with John
A. Geishecker, incorporated by reference to Exhibits
28.4 to the Company's Form S-8 Registration Statement
No. 33-37235 filed with the Securities and Exchange
Commission on October 9, 1990.

(6) Warrant and Stock Appreciation Rights Agreements,
dated January 12, 1989, with John A. Geishecker and
Saul Hymans, incorporated by reference to Exhibits
28.7 and 28.8 to the Company's Form S-8 Registration
Statement No. 33-37235 filed with the Securities and
Exchange Commission on October 9, 1990.

(7) Warrant Agreement, dated January 12, 1989, with Nina
I. McClelland, incorporated by reference to Exhibit
28.10 to the Company's Form S-8 Registration
Statement No. 33-37235 filed with the Securities and
Exchange Commission on October 9, 1990.

(8) Confidentiality, Anti-Competition and Termination
Benefits Agreement between Robert L. Buker and the
Company, incorporated by reference from Exhibit
10(11) to the Company's Form 10-K for year ended July
31, 1993.

12
13

(9) Confidentiality, Anti-Competition and Termination
Benefits Agreement between Eric Gelman and the
Company, incorporated by reference from Exhibit
10(12) to the Company's Form 10-K for year ended July
31, 1993.

(10) Warrant Agreement, dated September 2, 1992, with
Charles Newman, incorporated by reference from
Exhibit 10(14) to the Company's Form 10-K for year
ended July 31, 1993.

(11) Consent Judgment in Kelley v. Gelman Sciences Inc.
entered October 26, 1992, incorporated by reference
from Exhibit 10(15) to the Company's Form 10-K for
year ended July 31, 1993.

(12) Consent Judgment in State of Michigan v. Gelman
Sciences Inc. entered October 26, 1992, incorporated
by reference from Exhibit 10(16) to the Company's
Form 10-K for year ended July 31, 1993.

(13) Warrant Agreement, dated June 17, 1994, with Robert
Collins, incorporated by reference from Exhibit
10(16) to the Company's Form 10-K for the year ended
July 31, 1994.

(14) Warrant Agreement, dated June 17, 1994, with John
Geishecker, Jr, incorporated by reference from
Exhibit 10(17) to the Company's Form 10-K for the
year ended July 31, 1994

(15) Warrant Agreement, dated June 17, 1994, with Saul
Hymans, incorporated by reference from Exhibit 10(18)
to the Company's Form 10-K for the year ended July
31, 1994.

(16) Warrant Agreement, dated June 17, 1994, with Nina
McClelland, incorporated by reference from Exhibit
10(19) to the Company's Form 10-K for the year ended
July 31, 1994.

(17) Warrant Agreement, dated June 17, 1994, with Charles
Newman, incorporated by reference from Exhibit 10(20)
to the Company's Form 10-K for the year ended July
31, 1994.

(18) Confidentiality, Anti-Competition and Termination
Benefits Agreement between Mark A. Sutter and the
Company, incorporated by reference from Exhibit
10(21) to the Company's Form 10-K for the year ended
July 31, 1994.

(19) Confidentiality, Anti-Competition and Termination
Benefits Agreement between Edward J. Levitt and the
Company, incorporated by reference from Exhibit
10(22) to the Company's Form 10-K for the year ended
July 31, 1994.

(20) Warrant Agreement, dated September 2, 1994, with Dr.
Hajime Kimura, incorporated by reference from Exhibit
10(1) to the Company's Form 10-Q for the quarterly
period ended January 31, 1995.

(21) Employment Agreement dated August 1, 1995, between
the Company and Kim A. Davis.

(22) Employment Agreement dated August 1, 1995, between
the Company and Charles Gelman.

13
14

(11) Statement re computation of per share earnings for years ended July
31, 1995, 1994 and 1993.

(13) Annual Report to Shareholders for the year ended July 31, 1995.

(21) Subsidiaries of the Registrant.

(27) Financial Data Schedules

(b) Reports on Form 8-K

None

14
15

SIGNATURES

Pursuant to the requirements of Section 13 of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

By: Charles Gelman
--------------------------------------
GELMAN SCIENCES INC.
Charles Gelman, Chairman of the
Board and Chief Executive Officer
Dated: October 25, 1995

Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities indicated on October 25, 1995.

Charles Gelman
------------------------------------------------------------
Chairman of the Board and
Chief Executive Officer and Director

Kim A. Davis
------------------------------------------------------------
President and Chief Operating Officer

Karen A. Radtke
------------------------------------------------------------
Treasurer

David J. DiMaggio
------------------------------------------------------------
Controller

Robert M. Collins
------------------------------------------------------------
Director

John A. Geishecker, Jr.
------------------------------------------------------------
Director

Saul H. Hymans
------------------------------------------------------------
Director

Hajime Kimura, M.D., Ph.D.
------------------------------------------------------------
Director

Nina I. McClelland
------------------------------------------------------------
Director

Charles Newman
------------------------------------------------------------
Director

15
16

Coopers & Lybrand Coopers & Lybrand L.L.P.
a professional services firm

To the Board of Directors
and Stockholders of
Gelman Sciences Inc.:

Our report on the consolidated financial statements of Gelman Sciences Inc. and
subsidiaries has been incorporated by reference in this Form 10-K from page 25
of the 1995 Annual Report to Shareholders of Gelman Sciences Inc. In
connection with our audits of such financial statements, we have also audited
the related financial statement schedule listed in Part IV, Item 14 on page 17
of this Form 10-K.

In our opinion, the financial statement schedules referred to above, when
considered in relation to the basic financial statements taken as a whole,
present fairly, in all material respects, the information required to be
included therein.

/s/ Coopers & Lybrand L.L.P.

Detroit, Michigan
September 8, 1995

16
17

SCHEDULE II -- VALUATION AND
GELMAN SCIENCES INC. AND SUBSIDIARIES

COL. A COL. B COL. C COL. D COL. E COL. F
Additions
-------------------------------------
Charged to
Balance at Charged to other Balance at
beginning cost and accounts Deductions- end of
Description of period expenses describe (1) describe (2) period
- --------------------------------------------------------------------------------------------------------------------------------

YEAR ENDED JULY 31, 1995 $790,000 $564,000 ($14,000) $30,000 $1,310,000
Deducted from Asset Accounts-
Accounts Receivable Allowance

YEAR ENDED JULY 31, 1994 $927,000 $296,000 $8,000 $441,000 $790,000
Deducted from Asset Accounts-
Accounts Receivable Allowance

YEAR ENDED JULY 31, 1993 $749,000 $493,000 ($19,000) $296,000 $927,000
Deducted from Asset Accounts-
Accounts Receivable Allowance

(1) Change is due to the effect of exchange rate changes on translating
the allowance for accounts receivable account of foreign subsidiaries
in accordance with FASB Statement No. 52, "Foreign Currency Translation."

(2) Uncollectable accounts charged off, net of recoveries.

17
18

GELMAN SCIENCES INC.
FORM 10-K
INDEX TO EXHIBITS

(3) Articles of Incorporation and Bylaws

(2) Restated Bylaws

(10) Material Contracts

(21) Employment Agreement dated August 1, 1995, between the Company
and Kim A. Davis.

(22) Employment Agreement dated August 1, 1995, between the Company
and Charles Gelman.

(11) Statement re computation of per share earnings for years ended
July 31, 1995, 1994 and 1993

(13) Annual Report to Shareholders for the year ended July 31, 1995

(21) Subsidiaries of the Registrant

(27) Financial Data Schedules